Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure
Open Access
- 5 July 2020
- journal article
- research article
- Published by Wiley in Journal of Arrhythmia
- Vol. 36 (4) , 762-767
Abstract
Objectives: Ivabradine is a pharmacological agent used in patients with heart failure and sinus rhythm. Its only known pharmacological effect is to slow the heart rate. In this study, we investigated the impact of ivabradine on dyssynchrony parameters in heart failure patients.Methods: In this study, we assigned 55 patients taking medication for heart failure to receive ivabradine in addition (Group I). Twenty healthy volunteers comprised Group II. Echocardiographic measurements (dyssynchrony, left ventricular volumes and left ventricular ejection fraction) were taken at baseline, 1 month, and 3 months.Results: A total of 32 heart failure patients in Group I completed the study. There was significant improvement in dyssynchrony parameters after ivabradine treatment in Group I. Interventricular dyssynchrony (IVD) decreased from 42.0 ± 24.4 milliseconds at baseline to 33.6 ± 20.7 milliseconds at 1 month (P = .001) and to 30.7 ± 19.4 milliseconds at 3 months (P < .001). Septal to posterior wall motion delay decreased from 90.3 ± 21.4 milliseconds to 83.9 ± 26.9 milliseconds (P = .011) at 1 month and to 81.5 ± 27.3 milliseconds at 3 months (P = .001). Septal to lateral Ts delay (Ts‐SL) decreased from 42.7 ± 24.5 milliseconds to 35.8 ± 22.6 milliseconds at 1 month (P < .001) and to 34.8 ± 22.4 milliseconds at 3 months (P = .002). Left ventricular end‐systolic volume (LVESV) decreased from 139.4 ± 42.2 mL to 135.3 ± 39.6 mL at 1 month (P = .006) and to 123.3 ± 39.5 mL at 3 months (P < .001).Conclusion: The addition of ivabradine to heart failure treatment improves cardiac dyssynchrony parameters in chronic systolic heart failure patients with sinus rhythm.Keywords
This publication has 28 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyEuropean Heart Journal, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagenAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Funny channels in the control of cardiac rhythm and mode of action of selective blockersPharmacological Research, 2006
- Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical ProtocolAnnals of Noninvasive Electrocardiology, 2005
- Effects of Carvedilol Upon Intra- and Interventricular Synchrony in Patients With Chronic Heart FailureThe American Journal of Cardiology, 2005
- Segmental wall motion abnormalities in idiopathic dilated cardiomyopathy and their effect on prognosisThe American Journal of Cardiology, 2004
- Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart FailureCirculation, 2003